ALX2004 is a potential best- and first-in-class antibody-drug conjugate (ADC) for the treatment of EGFR-expressing solid tumors that was created ...

The FDA cleared the investigational new drug application for ALX2004, with phase 1 trials expected to begin in mid-2025 for ...

Scientists at F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have divulged prop-2-ynamide derivatives acting as EGFR (Exon 20 insertion [Ex20Ins] mutant) inhibitors reported to be useful for the ...

The FDA cleared the firm this week to begin a Phase I study of ALX2004 in EGFR-expressing solid tumors, which could start in a few months.

Tagrisso is associated with positive outcomes among patients with unresectable stage 3 EGFR-mutant non-small cell lung cancer ...

Savolitinib plus osimertinib may be a chemotherapy-free treatment option for patients with EGFR-mutant, advanced NSCLC with MET overexpression/amplification whose disease has progressed on osimertinib ...

The COCOON trial regimen reduced dermatologic side effects in patients with EGFR-mutant non-small cell lung cancer, phase 2 ...

Cullinan Therapeutics rebranded from oncology to immunology+oncology, focusing on CD19 TCEs for autoimmune diseases. Check ...

Beerse: Janssen-Cilag International NV, a Johnson & Johnson company, has received approval from the European Commission (EC) ...